AnaptysBio Inc. priced its initial public offering at $15 apiece.
The Calif.-based biotechnology company is looking to issue 5 million shares once it goes public. AnaptysBio has also granted underwriters a 30-day option to purchase up to an additional 750,000 of the shares offered.
The offering is expected to close Jan. 31.
Credit Suisse and Stifel are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-managers.
AnaptysBio is developing treatments for inflammation and cancers.